RT Journal Article
SR Electronic
T1 Clinical validation of Whole Genome Sequencing for routine cancer diagnostics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.29.20222091
DO 10.1101/2020.10.29.20222091
A1 Roepman, Paul
A1 de Bruijn, Ewart
A1 van Lieshout, Stef
A1 Schoenmaker, Lieke
A1 Boelens, Mirjam C
A1 Dubbink, Hendrikus J
A1 Geurts-Giele, Willemina RR
A1 Groenendijk, Floris H
A1 Huibers, Manon MH
A1 Kranendonk, Mariëtte EG
A1 Roemer, Margaretha GM
A1 Steehouwer, Marloes
A1 de Leng, Wendy WJ
A1 Hoischen, Alexander
A1 Ylstra, Bauke
A1 Monkhorst, Kim
A1 van der Hoeven, Jacobus JM
A1 Cuppen, Edwin
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.10.29.20222091.abstract
AB Whole genome sequencing (WGS) using tissue and matched blood samples from cancer patients is becoming in reach as the most complete genetic tumor diagnostic test. With a trend towards the availability of only small biopsies, and at the same time the need to screen for an increasing number of (complex) biomarkers, the use of a single all-inclusive test is preferred over multiple consecutive assays. To meet the high-quality diagnostics standards, we have optimized and validated the performance of a clinical grade WGS workflow, resulting in a technical success rate of 95.6% for samples with sufficient (≥20%) tumor cell percentage.Independent validation of identified biomarkers against commonly used diagnostic assays showed a high sensitivity (98.5%) and specificity (98.4%) for detection of somatic SNV and indels, and high concordance (93.3%) for gene amplification detection. Gene fusion analysis showed a concordance of 91.3% between DNA-based WGS and an orthogonal RNA-based gene fusion assay.Microsatellite (in)stability assessment showed a sensitivity of 100% with a specificity of 97%, and high-risk human papillomavirus detection showed an accuracy of 95.8% compared to standard pathological tests.In conclusion, whole genome sequencing has a >95% sensitivity and specificity compared to routinely used DNA techniques in diagnostics and all relevant mutation types can be detected reliably in a single assay.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For this study, samples were used from patients that were included as part of the CPCT-02 (NCT01855477), DRUP (NCT02925234) and WIDE (NL68609.031.18) clinical studies, which were approved by the medical ethical committees (METC) of the University Medical Center Utrecht and the Netherlands Cancer Institute.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw and analyzed WGS data used in this manuscript are available for validation and cancer research purposes through a standardized controlled access procedure (see https://www.hartwigmedicalfoundation.nl/applying-for-data/ for details). https://www.hartwigmedicalfoundation.nl/applying-for-data/